Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX-8371 · 1 trial · 5 indications
Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities
Incidence of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort 1 | EXPERIMENTAL | Escalating doses of CTX-8371 |
| Dose Expansion Cohort 2 | EXPERIMENTAL | Two CTX-8371 dose groups (3.0 mg/kg and 10.0 mg/kg) in three tumor type subgroups (NSCLC, TNBC, and HL) |
| Name | Type | Description |
|---|---|---|
| CTX-8371 | DRUG | Intravenous (IV) infusion every two weeks. |
Inclusion Criteria: 1. Age 18 years or older 2. Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/refractory to standard therapy or for which no effective standard therapy is available, including 1. M...
Top 20 of 83 competitors
CTX-8371 is an investigational small molecule being developed for the treatment of Non Small Cell Lung Cancer. It is currently in Phase 1 clinical development and is also being studied in other advanced malignancies including Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, and Malignant Melanoma.
CTX-8371 targets PD-L1, a protein involved in immune checkpoint regulation. By targeting PD-L1, the drug is designed to modulate the immune system's response to cancer cells. This mechanism is being evaluated in a Phase 1 clinical trial for patients with advanced malignancies.
CTX-8371 is being developed by Compass Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol CMPX. The company is currently conducting a Phase 1 clinical trial to evaluate the safety and efficacy of this investigational drug.
CTX-8371 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting patients to assess the drug's safety, tolerability, and preliminary efficacy in advanced malignancies.
CTX-8371 is being evaluated in a Phase 1 clinical trial with the identifier NCT06150664. This trial is titled 'A Phase 1 of CTX-8371 in Patients With Advanced Malignancies' and is currently recruiting participants in the United States. The study aims to enroll 85 patients aged 18 years and older.
CTX-8371 is a distinct investigational small molecule that targets PD-L1. While it shares a similar molecular target with other PD-L1 inhibitors, it is a unique drug candidate developed by Compass Therapeutics. Its specific chemical structure and properties differentiate it from other agents in this class.